News | June 03, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Subscribe To Our Newsletter & Stay Updated
